We are thrilled to announce that Append Medical has successfully raised $30 million in its latest funding round, a significant milestone that will propel our mission to revolutionize stroke prevention for patients with non-valvular atrial fibrillation. Our innovative Append Medical system is groundbreaking; designed to achieve complete Left Atrial Appendage (LAA) elimination without the need for any implantable devices, it addresses the critical challenge of blood clot leakage that so often leads to stroke. By utilizing our proprietary vacuum technology, we aim to disrupt the LAA occlusion market, eradicating the risks associated with Device-Related Thrombus (DRT) and Procedure-Related Leakage (PDL).
This funding will allow us to further streamline our technology and enhance our transcatheter solution, ensuring it can universally accommodate a broad range of patient anatomies. We are committed to improving patient outcomes through innovative medical solutions that are both safe and effective. Our team believes that no patient should have to face the debilitating consequences of stroke, and with this additional capital, we are one step closer to making our vision a reality. We extend our deepest gratitude to our investors for their belief in our mission and their continued support as we advance through pivotal phases of development and clinical evaluation. Together, we are on the forefront of changing the landscape of atrial fibrillation management, ensuring a healthier future for countless individuals worldwide.
